$1.21
9.01%
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US1511901050
Symbol
CELU

Celularity Inc - Ordinary Shares - Class A Stock price

$1.21
-0.81 40.10% 1M
-0.82 40.39% 6M
+0.10 9.01% YTD
-0.99 45.00% 1Y
-11.69 90.62% 3Y
-108.49 98.90% 5Y
-96.79 98.77% 10Y
-96.79 98.77% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.10 9.01%
ISIN
US1511901050
Symbol
CELU
Industry

Key metrics

Basic
Market capitalization
$34.5m
Enterprise Value
$74.3m
Net debt
$39.8m
Cash
$120.0k
Shares outstanding
28.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.8 | 1.4
EV/Sales
1.8 | 2.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
6.7%
Return on Equity
-654.9%
ROCE
-99.2%
ROIC
-58.5%
Debt/Equity
-2.0
Financials (TTM | estimate)
Revenue
$40.6m | $25.5m
EBITDA
$-47.0m | -
EBIT
$-48.5m | $-101.6m
Net Income
$-80.7m | $-139.9m
Free Cash Flow
$-6.6m
Growth (TTM | estimate)
Revenue
-15.8% | -53.0%
EBITDA
-23.3% | -
EBIT
-21.1% | -164.8%
Net Income
-131.0% | -141.7%
Free Cash Flow
50.9%
Margin (TTM | estimate)
Gross
50.6%
EBITDA
-115.9% | -
EBIT
-119.6%
Net
-198.9% | -548.6%
Free Cash Flow
-16.2%
More
EPS
$-3.1
FCF per Share
$-0.2
Short interest
6.3%
Employees
120
Rev per Employee
$450.0k
Show more

Is Celularity Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Celularity Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:

Buy
86%
Hold
14%

Financial data from Celularity Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
41 41
16% 16%
100%
- Direct Costs 20 20
16% 16%
49%
21 21
34% 34%
51%
- Selling and Administrative Expenses 52 52
7% 7%
129%
- Research and Development Expense 16 16
17% 17%
38%
-47 -47
23% 23%
-116%
- Depreciation and Amortization 1.49 1.49
23% 23%
4%
EBIT (Operating Income) EBIT -49 -49
21% 21%
-120%
Net Profit -81 -81
131% 131%
-199%

In millions USD.

Don't miss a Thing! We will send you all news about Celularity Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celularity Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
10 days ago
While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Rober...
Neutral
GlobeNewsWire
13 days ago
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.
Neutral
GlobeNewsWire
17 days ago
FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of Double...
More Celularity Inc - Ordinary Shares - Class A News

Company Profile

Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The firms CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company is headquartered in Florham Park, NJ.

Head office United States
CEO Robert Gordon
Employees 120
Founded 2016
Website celularity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today